Entrada Therapeutics (TRDA) CEO gets RSUs, options and tax-related share sales

Rhea-AI Filing Summary

Entrada Therapeutics CEO Dipal Doshi reported new equity awards and automatic tax-related share sales. On March 1, 2026, Doshi received 139,400 restricted stock units under the 2021 Stock Option and Incentive Plan and a stock option covering 208,000 shares of common stock, both granted at $0.00 per share.

The RSUs vest in four 25% installments each March 1 from 2027 through 2030, while 25% of the option vests on March 1, 2027 and the rest monthly through March 1, 2030. On March 2 and 3, 2026, a total of 29,050 shares of common stock were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum tax withholding, at weighted average prices of $11.6579 and $11.7564 per share.

Following these transactions, Doshi directly owned 526,014 shares of Entrada Therapeutics common stock.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Doshi Dipal

Role CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	19,181	$11.7564	$225K
Tax Withholding	Common Stock	9,869	$11.6579	$115K
Grant/Award	Stock Option (Right to Buy)	208,000	$0.00	--
Grant/Award	Common Stock	139,400	$0.00	--

Holdings After Transaction: Common Stock — 526,014 shares (Direct); Stock Option (Right to Buy) — 208,000 shares (Direct)

Footnotes (1)

1. Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Doshi Dipal

(Last) (First) (Middle)

C/O ENTRADA THERAPEUTICS, INC.

ONE DESIGN CENTER PLACE, SUITE 17-500

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Entrada Therapeutics, Inc. [ TRDA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/01/2026		A		139,400(1)	A	$0(1)	555,064	D
Common Stock	03/02/2026		F		9,869(2)	D	$11.6579(3)	545,195	D
Common Stock	03/03/2026		F		19,181(2)	D	$11.7564(4)	526,014	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$11.93	03/01/2026		A		208,000		(5)	03/01/2036	Common Stock	208,000	$0	208,000	D

Explanation of Responses:

1. Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.

2. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030.

Remarks:

	/s/ Jared Cohen, as Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Entrada Therapeutics (TRDA) CEO Dipal Doshi report on this Form 4?

Entrada Therapeutics CEO Dipal Doshi reported new equity awards and automatic tax-related share sales. He received restricted stock units and stock options, and some shares were sold automatically to cover tax withholding obligations under a mandatory sell-to-cover provision, not as discretionary trades.

How many RSUs and stock options did TRDA grant to its CEO Dipal Doshi?

Dipal Doshi received 139,400 restricted stock units and a stock option for 208,000 shares of Entrada Therapeutics common stock. Both awards were granted at a price of $0.00 per share under the company’s 2021 Stock Option and Incentive Plan, reflecting equity-based compensation.

What is the vesting schedule for Dipal Doshi’s new TRDA equity awards?

The 139,400 RSUs vest 25% each on March 1 of 2027, 2028, 2029, and 2030. The 208,000-share stock option vests 25% on March 1, 2027, with the remaining 75% vesting in thirty-six equal monthly installments through March 1, 2030.

Were the TRDA share sales by CEO Dipal Doshi discretionary trades?

The reported share sales were not discretionary trades by Dipal Doshi. Shares were automatically sold by the company under a mandatory sell-to-cover provision to satisfy minimum statutory tax withholding obligations associated with equity awards, at weighted average prices around the reported transaction values.

At what prices were Dipal Doshi’s TRDA shares sold to cover taxes?

On March 2 and 3, 2026, shares were sold at weighted average prices of $11.6579 and $11.7564. Footnotes state these were composed of multiple trades in ranges from $11.17 to $11.91 and from $11.22 to $12.095, executed to cover tax withholding.

How many Entrada Therapeutics (TRDA) shares does CEO Dipal Doshi hold after these transactions?

After the reported transactions, Dipal Doshi directly held 526,014 shares of Entrada Therapeutics common stock. This figure reflects his ownership following the automatic tax-related sales and the reporting of new equity awards, as disclosed in the Form 4 filing.